Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022

04.08.2022 -   IND clearance received from FDA for UCART20x22 for the treatment of Non-Hodgkin LymphomaCellectis unveiled novel immune-evasive universal allogeneic CAR T-cell in Nature Communications; awarded oral presentation at ASGCT in MayMr. Axel-Sven ...

Related Keywords

New York ,United States ,Paris ,France General ,France ,North Carolina ,Raleigh ,American ,Ashleyr Robinson ,Axel Sven Malkomes ,Donald Bergstrom ,Arthur Stril ,Les Laboratoires Servier ,Donalda Bergstrom ,Margaret Gandolfo ,Pascalyne Wilson ,Head Of Research ,Calyxt Inc ,Allogene Therapeutics Inc ,Linkedin ,American Society Of Cell ,Nature Communications On ,Cancer Research ,Cytovia Therapeutics Inc ,Relay Therapeutics Inc ,Iovance Biotherapeutics Inc ,Research Programs For ,International Accounting Standards Board ,Directors Of The Company Board ,International Financial Reporting Standards ,Securities Exchange Commission ,Allogeneic Cell Development Programs ,Youtube ,Company Board Of Directors On ,Group Share ,Non Hodgkin Lymphoma ,Cellectis Sponsored Phase ,American Society ,Gene Therapy Annual Meeting ,Nature Communications ,Natural Killer ,Laboratoires Servier ,Allogene Therapeutics ,Regenerative Medicine Advanced Therapy ,Largeb Cell Lymphoma ,Largeb Cell ,Chemistry Manufacturing ,Orphan Drug Designation ,Related Technologies ,Board Observer ,Executive Vice President ,Relay Therapeutics ,Sven Malkomes ,Chief Financial Officer ,Chief Business Officer ,Net Income ,Regarding Use ,Full Year ,United Statesa ,Nasdaq Global Market ,Euronext Growth ,Senior Manager ,Lifesci Advisors ,Private Securities Litigation Reform Act ,